Table 3.
Results of the multivariable analyses of DFS: NSABP B-42 10-year update
| Characteristic | Treatment group | Hazard ratio (95% CI) | P |
|---|---|---|---|
| Lowest BMD T-score | .04a | ||
| ≤ -2.0 | Placebo | 1.00 | |
| Letrozole | 0.67 (0.52 to 0.86) | ||
| > -2.0 | Placebo | 1.00 | |
| Letrozole | 0.91 (0.79 to 1.06) | ||
| Age, y | <.001 | ||
| Younger than 60 | 1.00 | ||
| 60 and older | 1.67 (1.44 to 1.95) | ||
| Pathologic nodal status | <.001 | ||
| Negative | 1.00 | ||
| Positive | 1.38 (1.21 to 1.57) | ||
| Received tamoxifen | <.001 | ||
| No | 1.00 | ||
| Yes | 0.76 (0.66 to 0.87) |
a
P interaction between treatment and T-score (for placebo, lowest T-score above -2.0 compared with no more than -2.0: HR = 0.74, 95% CI = 0.61 to 0.90; for letrozole lowest T-score: above -2.0 compared with no more than -2.0: HR = 1.01, 95% CI = 0.81 to 1.26). BMD = bone mineral density; DFS = disease-free survival; NSABP = National Surgical Adjuvant Breast and Bowel Project.